title: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
authors.forename: Jianlin
authors.initials: J
authors.lastname: Xu
authors.forename: Haitang
authors.initials: H
authors.lastname: Yang
authors.forename: Bo
authors.initials: B
authors.lastname: Jin
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Lou
authors.forename: Yanwei
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xueyan
authors.initials: X
authors.lastname: Zhang
authors.forename: Hua
authors.initials: H
authors.lastname: Zhong
authors.forename: Huiming
authors.initials: H
authors.lastname: Wang
authors.forename: Dan
authors.initials: D
authors.lastname: Wu
authors.forename: Baohui
authors.initials: B
authors.lastname: Han